The analyst rating for TRAD CHI MED (00570.HK) is Underweight, with a target price of HKD1.5, due to several factors. Morgan Stanley predicts a 70-80% chance of the stock price falling in the next 30 days, primarily because of a profit warning indicating that the company expects to record a loss in FY25 for the first time since 2013. Additionally, TRAD CHI MED is facing challenges from a shrinking market size and has not disclosed specific plans for expansion or exploring new markets through internal resources or mergers and acquisitions. This lack of visibility on its 2026 performance contributes to the expectation of further downside in the stock price.
